 | Study programme 2025-2026 | Français | |
| Les acides nucléiques, nouvelle source de thérapie personnalisée | |||
Learning Activity |
| Code | Lecturer(s) | Associate Lecturer(s) | Subsitute Lecturer(s) et other(s) | Establishment |
|---|---|---|---|---|
| M-BIMO-005 |
|
|
| Language of instruction | Language of assessment | HT(*) | HTPE(*) | HTPS(*) | HR(*) | HD(*) | Term |
|---|---|---|---|---|---|---|---|
| Français | Français | 10 | 0 | 0 | 0 | 0 | Q1 |
Content of Learning Activity
Reminder of the molecular biology dogma (DNA is transcribed into messenger RNA which will be translated into proteins) including the epigenome and the epitranscriptome. Extension of this dogma to non-coding RNAs. Overview of various strategies using RNA or DNA nucleic acids as drugs: RNA molecules (shRNA, siRNA, miRNA) for gene repression, antisense oligonucleotides, ribozymes, aptamers or RNA decoys as well as gene editing to inactivate or repair a gene (including the CRISPR/Cas9 system) and the production of mRNAs for vaccination. These molecules, used alone, in combination with other molecules or associated with a viral or non-viral vector, have been developed to treat rare (genetic) diseases in a personalised way, but not only! Viral diseases, cancers and other pathologies are also targeted by these molecules that have been developed for several decades. Various concrete examples will be discussed.
Required Learning Resources/Tools
powerpoint slides of the course
Recommended Learning Resources/Tools
Not applicable
Other Recommended Reading
Not applicable
Mode of delivery
- Hybrid
Type of Teaching Activity/Activities
- Cours magistraux
Evaluations
The assessment methods of the Learning Activity (AA) are specified in the course description of the corresponding Educational Component (UE)
Location of learning activity
- Université de Mons - Mons
Location of assessment
- Université de Mons - Mons